公开(公告)号：WO1997046881A1

公开(公告)日：1997-12-11

申请号：PCT/US1997009429

申请日：1997-06-03

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  POPE, Mark, R. ,  TARCHA, Peter, J. ,  MEES, David, R. ,  JOSEPH, Mary, K. ,  PRY, Terry, A. ,  PUTMAN, C., Brent ,  SUBOTICH, Daniel, T.

IPC: G01N33/543

CPC classification number: G01N33/54393 ,  G01N33/54353 ,  Y10S435/962 ,  Y10S435/963 ,  Y10S436/81 ,  Y10S436/823

Abstract: A method for increasing the binding activity of specific binding members bound to a solid phase material, e.g., a particle, that has been sterically stabilized. This increase in binding activity is brought about by degrading a steric stabilizer on the surface of the solid phase material. The method involves both immobilizing a specific binding member on the surface of a solid phase material and degrading a steric stabilizer on the surface of that solid phase material. In the preferred embodiment, the method involves the immobilization of a specific binding member on the surface of the sterically stabilized solid phase material, with subsequent degradation of the steric stabilizer.

Abstract translation: 用于增加与已经空间稳定的固相物质例如颗粒结合的特异性结合成员的结合活性的方法。 结合活性的这种增加是通过降解固相材料表面上的空间稳定剂引起的。 该方法包括将特定的结合构件固定在固相材料的表面上并降解固相材料表面上的空间稳定剂。 在优选的实施方案中，该方法包括将特定结合成分固定在空间稳定的固相材料的表面上，随后空间稳定剂的降解。

公开(公告)号：WO1997046709A2

公开(公告)日：1997-12-11

申请号：PCT/US1997009673

申请日：1997-06-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  CERNEY, Michael, B.

IPC: C12Q01/68

CPC classification number: C12Q1/689

Abstract: Nucleic acid sequences that are useful for detecting Chlamydia pneumoniae are herein provided. These sequences can be used in hybridization assays or amplification based assays designed to detect the presence of Chlamydia pneumoniae in a test sample. Additionally, the sequences can be provided as part of a kit.

Abstract translation: 本文提供了可用于检测肺炎衣原体的核酸序列。 这些序列可用于杂交测定或基于扩增的测定，其设计用于检测测试样品中肺炎衣原体的存在。 另外，序列可以作为试剂盒的一部分提供。

公开(公告)号：WO1997046554A1

公开(公告)日：1997-12-11

申请号：PCT/US1997009167

申请日：1997-06-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LIN, Nan-Horng ,  HE, Yun ,  HOLLADAY, Mark, W. ,  RYTHER, Keith ,  LI, Yihong ,  BAI, Hao

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds of formula (I) or the pharmaceutically-acceptable salts or prodrugs thereof are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. Key intermediates and processes using this key intermediates to produce compounds of formula (I) with the variables defined in the specification are also described.

Abstract translation: 式（I）的新型3-吡啶氧基甲基杂环醚化合物或其药学上可接受的盐或前药是神经元烟碱胆碱能通道受体的选择性和有效配体，并且有效控制突触传递。 还描述了使用这种关键中间体用式（I）化合物与说明书中定义的变量的关键中间体和方法。

公开(公告)号：WO1997039749A2

公开(公告)日：1997-10-30

申请号：PCT/US1997006897

申请日：1997-04-25

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  ABBRUZZESE, Bonnie, Chandler ,  McCAMISH, Mark, Anthony ,  COPE, Frederick, Oliver ,  DEMICHELE, Stephen, Joseph

IPC: A61K31/20

CPC classification number: A61K9/0029 ,  A23L33/12 ,  A23L33/16 ,  A23L33/175 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/202 ,  A61K31/70 ,  A61K47/12 ,  A61K47/183 ,  Y10S426/80 ,  Y10S426/801 ,  A23V2250/187 ,  A23V2250/1868 ,  A23V2250/708 ,  A23V2250/712 ,  A23V2250/1626 ,  A23V2250/5046 ,  A23V2250/211 ,  A23V2200/30 ,  A23V2200/308 ,  A23V2200/02

Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of omega -3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.

Abstract translation: 本发明涉及用于预防和治疗恶病质和厌食症的方法和营养组合物。 本发明的方法包括施用包含有效量的ω-3脂肪酸如α-亚麻酸，十八碳四烯酸，二十碳五烯酸，二十二碳五烯酸，二十二碳六烯酸或其混合物的组合物; 的支链氨基酸缬氨酸，亮氨酸，异亮氨酸或其混合物; 具有或不具有降低水平的色氨酸和5-羟色氨酸; 以及选自包含β-胡萝卜素，维生素C，维生素E，硒或其混合物的组的抗氧化剂系统。

公开(公告)号：WO1997036902A1

公开(公告)日：1997-10-09

申请号：PCT/US1997005069

申请日：1997-03-21

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  SHIOSAKI, Kazumi ,  GU, Yu, Gui ,  MICHAELIDES, Michael

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: A tetracyclic compound of formula (1) wherein A and the atoms to which it is attached comprise a pyridine ring selected from: (a), and (b), wherein R , R and R are specifically defined, which compounds are useful in the treatment of dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of substance abuse and other addictive behavior disorders, cognitive impairment and attention deficit disorder, and methods for the preparation thereof.

Abstract translation: 式（1）的四环化合物，其中A及其所连接的原子包含选自以下的吡啶环：（a）和（b），其中R 1，R 2和R 3为 具体定义，哪些化合物可用于治疗多巴胺相关的神经系统，心理和心血管疾病以及用于治疗药物滥用和其他成瘾行为障碍，认知障碍和注意力缺陷障碍及其制备方法。

公开(公告)号：WO1997035596A1

公开(公告)日：1997-10-02

申请号：PCT/US1997005364

申请日：1997-03-25

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  HALPIN-DOHNALEK, Margaret, I. ,  HILTY, Milo, D. ,  BYNUM, Douglas, G.

IPC: A61K35/74

CPC classification number: A61K35/747 ,  A23L29/065 ,  A61K35/745 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/491

Abstract: A novel method for the prevention of infectious diarrhea or diarrhea caused by antibiotic therapy is disclosed. The method comprises the steps of 1) mixing a powder comprising viable cultures of the probiotic organisms Lactobacillus reuteri, Lactobacillus acidophilus and Bifidobacterium infantis with a liquid; and 2) enterally administering the mixture to a mammal or a human. In a preferred embodiment at least 10 CFU (colony forming units) of each probiotic organism is consumed per day. The invention also relates to pills or capsules containing the probiotic system (Lactobacillus reuteri, Lactobacillus acidophilus and Bifidobacterium infantis) in a freeze dried or lyophilized form. The invention also relates to a novel powdered nutritional formula for the prevention of diarrhea that comprises protein, fat, carbohydrates and the microorganisms Lactobacillus reuteri, Lactobacillus acidophilus and Bifidobacterium infantis. In a preferred embodiment the powdered nutritional formula is a nutritionally complete infant formula. A large clinical study has shown that the probiotic system according to the invention when provided in a non-fermented form is efficacious in the prevention of diarrhea. Also disclosed is a method for manufacturing the formula of the invention.

Abstract translation: 公开了一种预防由抗生素治疗引起的感染性腹泻或腹泻的新方法。 该方法包括以下步骤：1）将包含益生菌生物体乳酸杆菌，嗜酸乳杆菌和婴儿双歧杆菌的活的培养物与液体混合; 和2）将混合物肠内施用于哺乳动物或人。 在优选的实施方案中，每天每个益生菌生物体的至少10 6 CFU（集落形成单位）被消耗。 本发明还涉及含有冻干或冻干形式的益生菌体系（嗜酸乳杆菌，嗜酸乳酸杆菌和婴儿双歧杆菌）的丸剂或胶囊。 本发明还涉及一种用于预防腹泻的新型粉状营养配方，其包含蛋白质，脂肪，碳水化合物和微生物乳酸乳杆菌，嗜酸乳杆菌和婴儿双歧杆菌。 在优选的实施方案中，粉状营养配方是营养完全的婴儿配方食品。 大量的临床研究表明，当以非发酵形式提供本发明的益生菌系统在预防腹泻方面是有效的。 还公开了制造本发明的配方的方法。

公开(公告)号：WO1997028428A1

公开(公告)日：1997-08-07

申请号：PCT/US1997000949

申请日：1997-01-30

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LINDBERG, John, M. ,  HEINZ, Robert, E.

IPC: G01J03/457

CPC classification number: G01J3/28 ,  G01J3/02 ,  G01J3/0208 ,  G01J3/0229 ,  G01J3/457 ,  G01J2003/1286 ,  G01J2003/2836 ,  G01J2003/2866

Abstract: The present invention provides a programmable filter for use as a standard in correlation spectrometers. Also provided is the use of the programmable standard in a process for determining the concentration of an optically absorbing compound. Also provided is a method and apparatus for noninvasively determining the concentration of an optically absorbing biological sample which incorporates the programmable standard of the invention. In one embodiment the programmable standard (20) contains a dispersive element (106a) and a transmissive spatial light modulator (108). Because the position of each light beam correlates to its wavelength, spatial filter (108) controllably and selectively attenuates desired wavelengths of the input beam.

Abstract translation: 本发明提供了一种用于相关光谱仪中的标准的可编程滤波器。 还提供了在用于确定光学吸收化合物的浓度的方法中使用可编程标准品。 还提供了用于非侵入性地确定结合了本发明的可编程标准的光学吸收生物样品的浓度的方法和装置。 在一个实施例中，可编程标准（20）包含色散元件（106a）和透射空间光调制器（108）。 由于每个光束的位置与其波长相关，所以空间滤波器（108）可控地选择性地衰减输入光束的期望波长。

公开(公告)号：WO1997026804A1

公开(公告)日：1997-07-31

申请号：PCT/US1997001138

申请日：1997-01-24

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MAZER, Terrence, Bruce ,  MILLER, Robert, A. ,  BARNICKI, Scott, D. ,  SUMNER, Charles, Edwan, Jr. ,  PHILLIPS, James, C. ,  McCOMBS, Charles, A.

IPC: A23L01/30

CPC classification number: A23L33/17 ,  A23L33/12 ,  A23L33/40 ,  Y10S426/80 ,  Y10S426/801

Abstract: This invention is directed to the use of triglycerides containing fatty ester moieties that include arachidonic acid (AA) and docosahexaenoic acid (DHA) in enteral nutritionals or nutritional supplements. These triglycerides are derived from lipid mixtures which have high levels of sterols and phosphorous. A preferred embodiment of the invention comprises an infant or enteral nutritional, or nutritional supplement, that comprises a lipid source derived form egg yolk. The lipid source derived from egg yolk is prepared by transesterification or hydrolysis, subjecting the mixture to distillation, and esterification with glycerin to result in a triglyceride containing the desired fatty acids of AA and DHA and little or no sterols and phosphorus.

Abstract translation: 本发明涉及含有花生四烯酸（AA）和二十二碳六烯酸（DHA）的脂肪酸酯部分的甘油三酯在肠内营养或营养补充剂中的用途。 这些甘油三酯衍生自具有高水平的甾醇和磷的脂质混合物。 本发明的优选实施方案包括婴儿或肠内营养或营养补充剂，其包含衍生自卵黄的脂质源。 来自蛋黄的脂质源通过酯交换或水解制备，使混合物蒸馏，并用甘油进行酯化，得到含有所需的AA和DHA脂肪酸的甘油三酯，很少或没有固醇和磷。

公开(公告)号：WO1997022335A1

公开(公告)日：1997-06-26

申请号：PCT/US1996018960

申请日：1996-11-25

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BOARD, Neville, W. ,  CARMODY, Alan, F. ,  FEELY, Liam, C. ,  WITHERS, Brian, C.

IPC: A61K09/20

CPC classification number: A61K31/7052 ,  A61K9/2013 ,  A61K9/205 ,  A61K31/165 ,  A61K31/4045 ,  A61K31/4164 ,  A61K31/5513 ,  A61K31/7048 ,  A61K31/706

Abstract: A controlled release, oral, solid, pharmaceutical composition for a reduced daily dosage regimen is described where the therapeutic ingredient is a poorly soluble basic drug. The formulation comprises the use of a water-soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid in admixture with the therapeutic drug. A particular embodiment comprising a once a day dosage form for clarithromycin is also described.

Abstract translation: 描述了用于减少日剂量方案的控释，口服，固体，药物组合物，其中治疗成分是难溶性碱性药物。 该制剂包括使用水溶性藻酸盐，海藻酸复合盐和有机羧酸与治疗药物的混合物。 还描述了包含克拉霉素的一天一次剂型的具体实施方案。

公开(公告)号：WO1997010863A1

公开(公告)日：1997-03-27

申请号：PCT/US1996014809

申请日：1996-09-16

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  OSBORNE, Robert, S. ,  PIONTEK, Carl, J. ,  CLEGG, Robert, D. ,  BUCK, Bradford, L. ,  FLEMING, Matthew, S. ,  WILSON, Grant, R. ,  PATTON, William, E. ,  ALEXANDER, Kathryn, E. ,  HARRIS, Jeremy, R. ,  LYON, William, F.

IPC: A61M05/142

CPC classification number: A61M5/142

Abstract: A fluid delivery set has three lengths of flexible tubing. The first length of flexible tubing at one end is connectable to or integral with a supply container for enteral or parenteral fluid, and at the other end is connected to the inlet of a drip chamber. The second length of flexible tubing is connected at one end to the outlet of the drip chamber, and at the other end to the inlet of a retention/connector device that has about a 90 DEG bend therein. The third length of flexible tubing is connected at one end to outlet of the retention/connector device, and at the other end is connectable to or integral with a means for introducing an enteral or parenteral fluid into the body of a patient. Preferably, a tension responsive pinch valve is operatively associated with the second length of flexible tubing.

Abstract translation: 流体输送组具有三段柔性管。 在一端的柔性管的第一长度可连接到用于肠内或肠胃外流体的供应容器或与其一体，并且另一端连接到滴注室的入口。 柔性管的第二长度在一端连接到滴水室的出口，另一端连接到其中具有大约90度弯曲的保持/连接器装置的入口。 柔性管的第三长度在一端连接到保持/连接器装置的出口，而另一端连接到或用于将肠内或肠胃外流体引入患者体内的装置。 优选地，张力响应夹紧阀可操作地与第二长度的柔性管相关联。